![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Despite advances in both drug and device treatment of chronic heart failure (CHF) over the last 20 years, many patients still progress to a stage of advanced CHF, characterized by increasing symptoms and declining functional status. Future drug management of such patients presents many challenges. This review focuses on the issue of optimizing standard medical therapy in advanced CHF, the treatment of diuretic resistance and hyponatremia. As well as prescribing drugs in this phase of the disease, the system of care used to deliver therapy is crucial. On its own, multiprofessional heart failure care can improve outcomes for these patients. Finally, this review also addresses the drugs and model of care used to deliver palliative care in the end stage of advanced CHF.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.